vs
ACI WORLDWIDE, INC.（ACIW）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是ACI WORLDWIDE, INC.的1.6倍（$772.1M vs $481.6M），ACI WORLDWIDE, INC.净利率更高（13.4% vs 12.7%，领先0.6%），ACI WORLDWIDE, INC.同比增速更快（6.3% vs 5.9%），Revvity自由现金流更多（$161.8M vs $116.6M），过去两年ACI WORLDWIDE, INC.的营收复合增速更高（23.4% vs 9.0%）
ACI Worldwide是全球领先的数字支付软件企业，总部位于美国内布拉斯加州埃尔克霍恩，为94个国家的客户提供服务，每日处理数十亿笔交易，总价值达数万亿美元。其智能解决方案服务于银行、金融机构、商户、账单服务商、收单机构、发卡机构及第三方支付服务商，支持全渠道搭建安全支付体系。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
ACIW vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.6倍
$481.6M
营收增速更快
ACIW
高出0.5%
5.9%
净利率更高
ACIW
高出0.6%
12.7%
自由现金流更多
RVTY
多$45.2M
$116.6M
两年增速更快
ACIW
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $481.6M | $772.1M |
| 净利润 | $64.3M | $98.4M |
| 毛利率 | 53.0% | — |
| 营业利润率 | 22.6% | 14.5% |
| 净利率 | 13.4% | 12.7% |
| 营收同比 | 6.3% | 5.9% |
| 净利润同比 | -34.7% | 3.9% |
| 每股收益（稀释后） | $0.61 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACIWRVTY
| Q4 25 | $481.6M | $772.1M | ||
| Q3 25 | $482.4M | $698.9M | ||
| Q2 25 | $401.3M | $720.3M | ||
| Q1 25 | $394.6M | $664.8M | ||
| Q4 24 | $453.0M | $729.4M | ||
| Q3 24 | $451.8M | $684.0M | ||
| Q2 24 | $373.5M | $691.7M | ||
| Q1 24 | $316.0M | $649.9M |
净利润ACIWRVTY
| Q4 25 | $64.3M | $98.4M | ||
| Q3 25 | $91.3M | $46.7M | ||
| Q2 25 | $12.2M | $53.9M | ||
| Q1 25 | $58.9M | $42.2M | ||
| Q4 24 | $98.6M | $94.6M | ||
| Q3 24 | $81.4M | $94.4M | ||
| Q2 24 | $30.9M | $55.4M | ||
| Q1 24 | $-7.8M | $26.0M |
毛利率ACIWRVTY
| Q4 25 | 53.0% | — | ||
| Q3 25 | 53.7% | 53.6% | ||
| Q2 25 | 41.5% | 54.5% | ||
| Q1 25 | 45.9% | 56.5% | ||
| Q4 24 | 55.8% | — | ||
| Q3 24 | 56.3% | 56.3% | ||
| Q2 24 | 45.6% | 55.7% | ||
| Q1 24 | 39.5% | 54.6% |
营业利润率ACIWRVTY
| Q4 25 | 22.6% | 14.5% | ||
| Q3 25 | 26.5% | 11.7% | ||
| Q2 25 | 8.7% | 12.6% | ||
| Q1 25 | 14.8% | 10.9% | ||
| Q4 24 | 27.0% | 16.3% | ||
| Q3 24 | 27.1% | 14.3% | ||
| Q2 24 | 14.4% | 12.4% | ||
| Q1 24 | 3.0% | 6.8% |
净利率ACIWRVTY
| Q4 25 | 13.4% | 12.7% | ||
| Q3 25 | 18.9% | 6.7% | ||
| Q2 25 | 3.0% | 7.5% | ||
| Q1 25 | 14.9% | 6.4% | ||
| Q4 24 | 21.8% | 13.0% | ||
| Q3 24 | 18.0% | 13.8% | ||
| Q2 24 | 8.3% | 8.0% | ||
| Q1 24 | -2.5% | 4.0% |
每股收益（稀释后）ACIWRVTY
| Q4 25 | $0.61 | $0.86 | ||
| Q3 25 | $0.88 | $0.40 | ||
| Q2 25 | $0.12 | $0.46 | ||
| Q1 25 | $0.55 | $0.35 | ||
| Q4 24 | $0.92 | $0.77 | ||
| Q3 24 | $0.77 | $0.77 | ||
| Q2 24 | $0.29 | $0.45 | ||
| Q1 24 | $-0.07 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $196.5M | $919.9M |
| 总债务越低越好 | $817.6M | — |
| 股东权益账面价值 | $1.5B | $7.3B |
| 总资产 | $3.1B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.54× | — |
8季度趋势，按日历期对齐
现金及短期投资ACIWRVTY
| Q4 25 | $196.5M | $919.9M | ||
| Q3 25 | $199.3M | $931.4M | ||
| Q2 25 | $189.7M | $991.8M | ||
| Q1 25 | $230.1M | $1.1B | ||
| Q4 24 | $216.4M | $1.2B | ||
| Q3 24 | $177.9M | $1.2B | ||
| Q2 24 | $157.0M | $2.0B | ||
| Q1 24 | $183.4M | $1.7B |
总债务ACIWRVTY
| Q4 25 | $817.6M | — | ||
| Q3 25 | $867.8M | — | ||
| Q2 25 | $898.0M | — | ||
| Q1 25 | $845.9M | — | ||
| Q4 24 | $924.6M | — | ||
| Q3 24 | $994.3M | — | ||
| Q2 24 | $1.0B | — | ||
| Q1 24 | $1.0B | — |
股东权益ACIWRVTY
| Q4 25 | $1.5B | $7.3B | ||
| Q3 25 | $1.5B | $7.4B | ||
| Q2 25 | $1.4B | $7.6B | ||
| Q1 25 | $1.5B | $7.6B | ||
| Q4 24 | $1.4B | $7.7B | ||
| Q3 24 | $1.3B | $7.9B | ||
| Q2 24 | $1.2B | $7.9B | ||
| Q1 24 | $1.3B | $7.8B |
总资产ACIWRVTY
| Q4 25 | $3.1B | $12.2B | ||
| Q3 25 | $3.2B | $12.1B | ||
| Q2 25 | $3.1B | $12.4B | ||
| Q1 25 | $3.2B | $12.4B | ||
| Q4 24 | $3.0B | $12.4B | ||
| Q3 24 | $3.1B | $12.8B | ||
| Q2 24 | $3.4B | $13.4B | ||
| Q1 24 | $3.3B | $13.4B |
负债/权益比ACIWRVTY
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.59× | — | ||
| Q2 25 | 0.64× | — | ||
| Q1 25 | 0.57× | — | ||
| Q4 24 | 0.65× | — | ||
| Q3 24 | 0.75× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.81× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $121.8M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $116.6M | $161.8M |
| 自由现金流率自由现金流/营收 | 24.2% | 21.0% |
| 资本支出强度资本支出/营收 | 1.1% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.89× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $309.9M | $509.4M |
8季度趋势，按日历期对齐
经营现金流ACIWRVTY
| Q4 25 | $121.8M | $182.0M | ||
| Q3 25 | $73.0M | $138.5M | ||
| Q2 25 | $49.8M | $134.3M | ||
| Q1 25 | $78.2M | $128.2M | ||
| Q4 24 | $126.5M | $174.2M | ||
| Q3 24 | $54.0M | $147.9M | ||
| Q2 24 | $55.0M | $158.6M | ||
| Q1 24 | $123.2M | $147.6M |
自由现金流ACIWRVTY
| Q4 25 | $116.6M | $161.8M | ||
| Q3 25 | $69.6M | $120.0M | ||
| Q2 25 | $47.6M | $115.5M | ||
| Q1 25 | $76.1M | $112.2M | ||
| Q4 24 | $119.5M | $149.8M | ||
| Q3 24 | $50.5M | $125.6M | ||
| Q2 24 | $53.3M | $136.6M | ||
| Q1 24 | $120.0M | $129.7M |
自由现金流率ACIWRVTY
| Q4 25 | 24.2% | 21.0% | ||
| Q3 25 | 14.4% | 17.2% | ||
| Q2 25 | 11.9% | 16.0% | ||
| Q1 25 | 19.3% | 16.9% | ||
| Q4 24 | 26.4% | 20.5% | ||
| Q3 24 | 11.2% | 18.4% | ||
| Q2 24 | 14.3% | 19.7% | ||
| Q1 24 | 38.0% | 20.0% |
资本支出强度ACIWRVTY
| Q4 25 | 1.1% | 2.6% | ||
| Q3 25 | 0.7% | 2.6% | ||
| Q2 25 | 0.5% | 2.6% | ||
| Q1 25 | 0.5% | 2.4% | ||
| Q4 24 | 1.5% | 3.4% | ||
| Q3 24 | 0.8% | 3.3% | ||
| Q2 24 | 0.5% | 3.2% | ||
| Q1 24 | 1.0% | 2.7% |
现金转化率ACIWRVTY
| Q4 25 | 1.89× | 1.85× | ||
| Q3 25 | 0.80× | 2.97× | ||
| Q2 25 | 4.08× | 2.49× | ||
| Q1 25 | 1.33× | 3.03× | ||
| Q4 24 | 1.28× | 1.84× | ||
| Q3 24 | 0.66× | 1.57× | ||
| Q2 24 | 1.78× | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACIW
| Issuing And Acquiring | $183.7M | 38% |
| License | $158.3M | 33% |
| Maintenance | $50.8M | 11% |
| Software And Platform Service | $49.6M | 10% |
| Merchant Payments | $42.4M | 9% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
